B cells expressing mutated IGHV1-69-encoded antigen receptors related to virus neutralization show lymphoma-like transcriptomes in patients with chronic HCV infection.
Humans
Hepatitis C, Chronic
/ immunology
Receptors, Antigen, B-Cell
/ genetics
Transcriptome
B-Lymphocytes
/ immunology
Hepacivirus
/ immunology
Sustained Virologic Response
Lymphoma, Large B-Cell, Diffuse
/ immunology
Antibodies, Neutralizing
/ immunology
Complementarity Determining Regions
/ genetics
Male
Antiviral Agents
/ therapeutic use
Mutation
Female
Middle Aged
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
14
11
2023
accepted:
11
05
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Chronic HCV infection leads to a complex interplay with adaptive immune cells that may result in B cell dyscrasias like cryoglobulinemia or lymphoma. While direct-acting antiviral therapy has decreased the incidence of severe liver damage, its effect on extrahepatic HCV manifestations such as B cell dyscrasias is still unclear. We sequenced B cell receptor (BCR) repertoires in patients with chronic HCV mono-infection and patients with HCV with a sustained virological response (SVR) after direct-acting antiviral therapy. This data set was mined for highly neutralizing HCV antibodies and compared to a diffuse large B cell lymphoma data set. The TKO model was used to test the signaling strength of selected B-BCRs in vitro. Single-cell RNA sequencing of chronic HCV and HCV SVR samples was performed to analyze the transcriptome of B cells with HCV-neutralizing antigen receptors. We identified a B cell fingerprint with high richness and somatic hypermutation in patients with chronic HCV and SVR. Convergence to specific immunoglobulin genes produced high-connectivity complementarity-determining region 3 networks. In addition, we observed that IGHV1-69 CDR1 and FR3 mutations characterizing highly neutralizing HCV antibodies corresponded to recurrent point mutations found in clonotypic BCRs of high-grade lymphomas. These BCRs did not show autonomous signaling but a lower activation threshold in an in vitro cell model for the assessment of BCR signaling strength. Single-cell RNA sequencing revealed that B cells carrying these point mutations showed a persisting oncogenic transcriptome signature with dysregulation in signaling nodes such as CARD11, MALT1, RelB, MAPK, and NFAT. We provide evidence that lymphoma-like cells derive from the anti-HCV immune response. In many patients, these cells persist for years after SVR and can be interpreted as a mechanistic basis for HCV-related B cell dyscrasias and increased lymphoma risk even beyond viral elimination.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic HCV infection leads to a complex interplay with adaptive immune cells that may result in B cell dyscrasias like cryoglobulinemia or lymphoma. While direct-acting antiviral therapy has decreased the incidence of severe liver damage, its effect on extrahepatic HCV manifestations such as B cell dyscrasias is still unclear.
METHODS
METHODS
We sequenced B cell receptor (BCR) repertoires in patients with chronic HCV mono-infection and patients with HCV with a sustained virological response (SVR) after direct-acting antiviral therapy. This data set was mined for highly neutralizing HCV antibodies and compared to a diffuse large B cell lymphoma data set. The TKO model was used to test the signaling strength of selected B-BCRs in vitro. Single-cell RNA sequencing of chronic HCV and HCV SVR samples was performed to analyze the transcriptome of B cells with HCV-neutralizing antigen receptors.
RESULTS
RESULTS
We identified a B cell fingerprint with high richness and somatic hypermutation in patients with chronic HCV and SVR. Convergence to specific immunoglobulin genes produced high-connectivity complementarity-determining region 3 networks. In addition, we observed that IGHV1-69 CDR1 and FR3 mutations characterizing highly neutralizing HCV antibodies corresponded to recurrent point mutations found in clonotypic BCRs of high-grade lymphomas. These BCRs did not show autonomous signaling but a lower activation threshold in an in vitro cell model for the assessment of BCR signaling strength. Single-cell RNA sequencing revealed that B cells carrying these point mutations showed a persisting oncogenic transcriptome signature with dysregulation in signaling nodes such as CARD11, MALT1, RelB, MAPK, and NFAT.
CONCLUSIONS
CONCLUSIONS
We provide evidence that lymphoma-like cells derive from the anti-HCV immune response. In many patients, these cells persist for years after SVR and can be interpreted as a mechanistic basis for HCV-related B cell dyscrasias and increased lymphoma risk even beyond viral elimination.
Identifiants
pubmed: 39082968
doi: 10.1097/HC9.0000000000000503
pii: 02009842-202408010-00019
pii:
doi:
Substances chimiques
Receptors, Antigen, B-Cell
0
Antibodies, Neutralizing
0
Complementarity Determining Regions
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006.
Spearman CW, Dusheiko GM, Hellard M, Sonderup M, Hepatitis C. Lancet. 2019;394:1451–1466.
Couronne L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, et al. From hepatitis C virus infection to B cell lymphoma. Ann Oncol. 2018;29:92–100.
Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B cell subset. Blood. 2011;117:5425–5437.
Gauthiez E, Habfast-Robertson I, Rueger S, Kutalik Z, Aubert V, Berg T, et al. A systematic review and meta-analysis of HCV clearance. Liver Int. 2017;37:1431–1445.
Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol. 2009;6:217–227.
Borderia AV, Rozen-Gagnon K, Vignuzzi M. Fidelity variants and RNA quasispecies. Curr Top Microbiol Immunol. 2016;392:303–322.
Hensel N, Gu Z, Sagar, Wieland D, Jechow K, Kemming J, et al. Memory-like HCV-specific CD8(+) T cells retain a molecular scar after cure of chronic HCV infection. Nat Immunol. 2021;22:229–239.
Wildner NH, Walker A, Brauneck F, Ditt V, Peine S, Huber S, et al. Transcriptional pattern analysis of virus-specific CD8+ T cells in hepatitis C infection: Increased expression of TOX and eomesodermin during and after persistent antigen recognition. Front Immunol. 2022;13:886646.
Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol. 2007;60:1378–1383.
Libra M, Gasparotto D, Gloghini A, Navolanic PM, De Re V, Carbone A. Hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci. 2005;10:2460–2471.
De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000;96:3578–3584.
Kostareli E, Gounari M, Janus A, Murray F, Brochet X, Giudicelli V, et al. Antigen receptor stereotypy across B cell lymphoproliferations: The case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia. 2012;26:1127–1131.
Janjua NZ, Wong S, Abdia Y, Jeong D, Buller-Taylor T, Adu PA, et al. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. J Hepatol. 2021;75:1049–1057.
Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74:1053–1063.
Schultheiss C, Simnica D, Willscher E, Oberle A, Fanchi L, Bonzanni N, et al. Next-generation immunosequencing reveals pathological T-cell architecture in autoimmune hepatitis. Hepatology. 2021;73:1436–1448.
Simnica D, Schliffke S, Schultheiss C, Bonzanni N, Fanchi LF, Akyuz N, et al. High-throughput immunogenetics reveals a lack of physiological T cell clusters in patients with autoimmune cytopenias. Front Immunol. 2019;10:1897.
Schultheiss C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity. 2020;53:442–455 e444.
Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: An immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013;41:W34–W40.
Schultheiß C, Paschold L, Willscher E, Simnica D, Wöstemeier A, Muscate F, et al. Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19. iScience. 2021;24:103325.
Moon KR, van Dijk D, Wang Z, Gigante S, Burkhardt DB, Chen WS, et al. Visualizing structure and transitions in high-dimensional biological data. Nat Biotechnol. 2019;37:1482–1492.
Meixlsperger S, Kohler F, Wossning T, Reppel M, Muschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity. 2007;26:323–333.
Weber T, Potthoff J, Bizu S, Labuhn M, Dold L, Schoofs T, et al. Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity. 2022;55:341–354 e347.
Tucci FA, Kitanovski S, Johansson P, Klein-Hitpass L, Kahraman A, Durig J, et al. Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals. Blood. 2018;131:546–557.
Miho E, Roskar R, Greiff V, Reddy ST. Large-scale network analysis reveals the sequence space architecture of antibody repertoires. Nat Commun. 2019;10:1321.
Young RM, Wu T, Schmitz R, Dawood M, Xiao W, Phelan JD, et al. Survival of human lymphoma cells requires B cell receptor engagement by self-antigens. Proc Natl Acad Sci USA. 2015;112:13447–13454.
Holla P, Dizon B, Ambegaonkar AA, Rogel N, Goldschmidt E, Boddapati AK, et al. Shared transcriptional profiles of atypical B cells suggest common drivers of expansion and function in malaria, HIV, and autoimmunity. Sci Adv. 2021;7:eabg8384.
Sutton HJ, Aye R, Idris AH, Vistein R, Nduati E, Kai O, et al. Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. Cell Rep. 2021;34:108684.
Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998;91:2433–2442.
Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B cell lymphoma. Am J Pathol. 2001;159:253–261.
Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gosch B, et al. Complementarity determining region-independent recognition of a superantigen by B cell antigen receptors of mantle cell lymphoma. Haematologica. 2016;101:e378–e381.
Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, et al. Stereotyped B cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies. Blood. 2012;119:4467–4475.
Spies E, Fichtner M, Muller F, Krasemann S, Illerhaus G, Glatzel M, et al. Comment on “Primary central nervous system (CNS) lymphoma B cell receptors recognize CNS proteins”. J Immunol. 2015;195:4549–4550.
Binder M, Muller F, Frick M, Wehr C, Simon F, Leistler B, et al. CLL B cell receptors can recognize themselves: Alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood. 2013;121:239–241.
Binder M, Lechenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, et al. Stereotypical chronic lymphocytic leukemia B cell receptors recognize survival promoting antigens on stromal cells. PLoS One. 2010;5:e15992.
Minden MD-V, Übelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489:309–312.
Maity PC, Bilal M, Koning MT, Young M, van Bergen CAM, Renna V, et al. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc Natl Acad Sci USA. 2020;117:4320–4327.
Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, Tasdogan A, et al. Distinct homotypic B cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun. 2017;8:15746.
Paschold L, Simnica D, Brito RB, Zhang T, Schultheiss C, Dierks C, et al. Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21(R110) chronic lymphocytic leukemia. Blood Cancer J. 2022;12:49.
Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12:229–243.
Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: The clinical perspective. Hepatology. 2012;55:634–641.
Ma X, Zhu Y, Dong D, Chen Y, Wang S, Yang D, et al. Cryo-EM structures of two human B cell receptor isotypes. Science. 2022;377:880–885.
Liu W, Meckel T, Tolar P, Sohn HW, Pierce SK. Antigen affinity discrimination is an intrinsic function of the B cell receptor. J Exp Med. 2010;207:1095–1111.
Tolar P, Hanna J, Krueger PD, Pierce SK. The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity. 2009;30:44–55.
Stamatopoulos B, Smith T, Crompot E, Pieters K, Clifford R, Mraz M, et al. The light chain IgLV3-21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia: Results of a multicenter study. Clin Cancer Res. 2018;24:5048–5057.
Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology. 2014;59:2140–2151.
Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, et al. Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection. Cell Host Microbe. 2018;24:717–730.e715.
Racanelli V, Brunetti C, De Re V, Caggiari L, De Zorzi M, Leone P, et al. Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections. PLoS One. 2011;6:e25606.
Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic malignancies after treatment with direct antiviral agents for chronic HCV infection. J Gastrointest Cancer. 2020;51:584–590.
El-Serag HB, Christie IC, Puenpatom A, Castillo D, Kanwal F, Kramer JR. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019;49:1442–1447.